Estrella Immunopharma (ESLA) News Today $1.48 -0.01 (-0.67%) Closing price 04:00 PM EasternExtended Trading$1.48 0.00 (-0.07%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Estrella Immunopharma completes first dose cohort in STARLIGHT trialFebruary 21 at 5:25 PM | markets.businessinsider.comEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose CohortFebruary 21 at 9:09 AM | businesswire.comD. Boral Capital Begins Coverage on Estrella Immunopharma (NASDAQ:ESLA)February 20 at 2:31 AM | americanbankingnews.comEstrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral CapitalFebruary 19 at 4:46 PM | businesswire.comD. Boral Capital Initiates Coverage of Estrella Immunopharma (ESLA) with Buy RecommendationFebruary 19 at 5:48 AM | msn.comSpotlight On US Penny Stocks: Estrella Immunopharma And Two Others To ConsiderNovember 19, 2024 | uk.finance.yahoo.comEstrella Immunopharma (NASDAQ:ESLA) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comEstrella Immunopharma (NASDAQ:ESLA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comEstrella Immunopharma Shares Rise on Lymphoma Patient's Treatment ResponseSeptember 28, 2024 | marketwatch.comEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cellsSeptember 27, 2024 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLAW)August 24, 2024 | uk.finance.yahoo.comEstrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest UpdateEstrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 19,100 shares, an increase of 8.5% from the June 30th total of 17,600 shares. Based on an average trading volume of 17,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.2% of the shares of the stock are short sold.July 30, 2024 | marketbeat.comESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024May 20, 2024 | investorplace.comEntheon Biomedical Corp. (ENTBD)March 7, 2024 | finance.yahoo.comEstrella Immunopharma Approves $1 Million Stock Buyback ProgramFebruary 1, 2024 | msn.comWhy DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving PremarketJanuary 17, 2024 | msn.comEstrella Immunopharma Inc (ESLA)November 23, 2023 | uk.investing.comEstrella Immunopharma, Inc. (ESLA)November 3, 2023 | finance.yahoo.comEstrella Immunopharma Inc ESLANovember 1, 2023 | morningstar.comWe Think Estrella Immunopharma (NASDAQ:ESLA) Can Afford To Drive Business GrowthOctober 20, 2023 | finance.yahoo.comTrading was temporarily halted for "ESLA" at 09:10 AM with a stated reason of "LULD pause."October 2, 2023 | marketbeat.com Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address ESLA Media Mentions By Week ESLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESLA News Sentiment▼0.250.60▲Average Medical News Sentiment ESLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESLA Articles This Week▼60▲ESLA Articles Average Week Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zentalis Pharmaceuticals News Today CARGO Therapeutics News Today Vaxart News Today Acrivon Therapeutics News Today Cidara Therapeutics News Today Alector News Today Aclaris Therapeutics News Today Inhibikase Therapeutics News Today Greenwich LifeSciences News Today Innate Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESLA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
